7-Bromo-1-heptanol
Based on 1 Customer Validation
7-Bromo-1-heptanol (7-Bromoheptan-1-ol) acts as a HaloTag-GPSM2 inhibitor and an organic synthesis intermediate. It forms a covalent irreversible bond with HaloTag-GPSM2, thereby blocking the subsequent labeling effect of fluorescent HaloTag ligands and enabling pulse-chase analysis of protein turnover. 7-Bromo-1-heptanol can be used to synthesize PROTAC BET degraders and multivalent glycoporphyrin antiviral compounds. It is applicable to cancer-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.15%
- CAS No.: 10160-24-4
- Formule: C7H15BrO
- Masse moléculaire:195.10
-
Stockage:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
7-Bromo-1-heptanol (30 μg/mL; 30 min pre-incubation, 1-6 h treatment) acts as a HaloTag ligand to enable detection of ER-phagy in MEFs stably expressing Halo-mGFP-KDEL[3].
7-Bromo-1-heptanol (30 μg/mL; 6 h) acts as a HaloTag ligand to enable detection of mitophagy in MEFs stably expressing pSu9-Halo-mGFP[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:mouse embryonic fibroblasts (MEFs) stably expressing Halo-mGFP-KDEL
-
Concentration:30 μg/mL
-
Incubation Time:30 min (pre-incubation); 1 h, 6 h (treatment)
-
Result:Enabled detection of ER-phagy via western blot quantification of resistant Halo monomer under complete media and starvation conditions.
-
Cell Line:mouse embryonic fibroblasts (MEFs) stably expressing pSu9-Halo-mGFP
-
Concentration:30 μg/mL
-
Incubation Time:6 h
-
Result:Enabled detection of mitophagy via western blot quantification of resistant Halo monomer under complete media and starvation conditions.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Gpsm2^HaloTag/+ (6 weeks old)[1]
-
Dosage:100 µM
-
Administration:posterior semicircular canal injection; single dose
-
Result:Recorded no or minimal TMR signals (indicating newly synthesized HaloTag-GPSM2) in operated ears up to 3 days post-injection.
Showed steadily increasing TMR signals from 3 to 14 days postsurgery in an exponential pattern, with signals not reaching control levels even after 4 or 6 weeks.
Revealed a GPSM2 half-life of 9.05 days at stereocilia tips via nonlinear regression analysis of signal data.
Chemical Information
-
CAS No. 10160-24-4
-
Appearance Solid-Liquid Mixture
-
Masse moléculaire 195.10
-
Formule C7H15BrO
-
Color Colorless to light yellow
-
SMILES
BrCCCCCCCO
-
Synonyms
7-Bromoheptan-1-ol
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvant et solubilité
DMSO : ≥ 100 mg/mL (512.56 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (25.63 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (25.63 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.1256 mL | 25.6279 mL | 51.2558 mL | 128.1394 mL |
| 5 mM | 1.0251 mL | 5.1256 mL | 10.2512 mL | 25.6279 mL | |
| 10 mM | 0.5126 mL | 2.5628 mL | 5.1256 mL | 12.8139 mL | |
| 15 mM | 0.3417 mL | 1.7085 mL | 3.4171 mL | 8.5426 mL | |
| 20 mM | 0.2563 mL | 1.2814 mL | 2.5628 mL | 6.4070 mL | |
| 25 mM | 0.2050 mL | 1.0251 mL | 2.0502 mL | 5.1256 mL | |
| 30 mM | 0.1709 mL | 0.8543 mL | 1.7085 mL | 4.2713 mL | |
| 40 mM | 0.1281 mL | 0.6407 mL | 1.2814 mL | 3.2035 mL | |
| 50 mM | 0.1025 mL | 0.5126 mL | 1.0251 mL | 2.5628 mL | |
| 60 mM | 0.0854 mL | 0.4271 mL | 0.8543 mL | 2.1357 mL | |
| 80 mM | 0.0641 mL | 0.3203 mL | 0.6407 mL | 1.6017 mL | |
| 100 mM | 0.0513 mL | 0.2563 mL | 0.5126 mL | 1.2814 mL |
7-Bromo-1-heptanol Related Classifications
HY-W008425 Related Classifications
Powered by Bioz
- 7-Bromo-1-heptanol
- 10160-24-4
- 7-Bromoheptan-1-ol
- Biochemical Assay Reagents
- Drug Intermediate
- 1,7-heptanediol
- HaloTag-GPSM2
- tetrabutylammonium iodide
- 1-butyl-3-methylimidazolium hydrogensulphate
- Halo-mGFP-KDEL
- MEFs
- 48% aqueous hydrogen bromide
- pSu9-Halo-mGFP
- 3,4-dihydro-2H-pyran
- inner hair cell stereocilia tips
- Inhibitor
- inhibitor
- inhibit